These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. Siesling S, Zwinderman AH, van Vugt JP, Kieburtz K, Roos RA. Mov Disord; 1997 Mar; 12(2):229-34. PubMed ID: 9087982 [Abstract] [Full Text] [Related]
6. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning. Reedeker N, Van Der Mast RC, Giltay EJ, Van Duijn E, Roos RA. Mov Disord; 2010 Aug 15; 25(11):1612-8. PubMed ID: 20629165 [Abstract] [Full Text] [Related]
7. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I, Parkinson Study Group. Mov Disord; 2002 Jul 15; 17(4):758-63. PubMed ID: 12210871 [Abstract] [Full Text] [Related]
8. A controlled trial of idebenone in Huntington's disease. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, Folstein MF, Brandt J, Ross CA, Folstein SE. Mov Disord; 1996 Sep 15; 11(5):549-54. PubMed ID: 8866496 [Abstract] [Full Text] [Related]
9. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. Alzheimers Dement; 2009 Sep 15; 5(5):375-9. PubMed ID: 19751916 [Abstract] [Full Text] [Related]
10. The development and validation of a carer questionnaire to assess cognitive function in neuropsychiatric patients. Randhawa S, Walterfang M, Miller K, Scholes A, Mocellin R, Velakoulis D. J Psychosom Res; 2007 Jul 15; 63(1):93-8. PubMed ID: 17586342 [Abstract] [Full Text] [Related]
11. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F. Mov Disord; 1994 Jan 15; 9(1):76-83. PubMed ID: 8139608 [Abstract] [Full Text] [Related]
12. Validation of the Korean version of the Bayer activities of daily living scale. Choi SH, Na DL, Lee BH, Kang SJ, Ha CK, Han SH, Erzigkeit H. Hum Psychopharmacol; 2003 Aug 15; 18(6):469-75. PubMed ID: 12923826 [Abstract] [Full Text] [Related]
13. Correlates of early disability in Huntington's disease. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S. Ann Neurol; 1986 Dec 15; 20(6):727-31. PubMed ID: 2949692 [Abstract] [Full Text] [Related]
14. Performance-Based instrument to assess functional capacity in dementia: The Texas Functional Living Scale. Cullum CM, Saine K, Chan LD, Martin-Cook K, Gray KF, Weiner MF. Neuropsychiatry Neuropsychol Behav Neurol; 2001 Dec 15; 14(2):103-8. PubMed ID: 11417663 [Abstract] [Full Text] [Related]
17. Factors contributing to institutionalization in patients with Huntington's disease. Rosenblatt A, Kumar BV, Margolis RL, Welsh CS, Ross CA. Mov Disord; 2011 Aug 01; 26(9):1711-6. PubMed ID: 21538527 [Abstract] [Full Text] [Related]
18. Assessment of coenzyme Q10 tolerability in Huntington's disease. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Mov Disord; 1996 May 01; 11(3):321-3. PubMed ID: 8723151 [Abstract] [Full Text] [Related]
19. Functional decline in Huntington's disease. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I. Mov Disord; 1995 Mar 01; 10(2):211-4. PubMed ID: 7753064 [Abstract] [Full Text] [Related]